So reports Thomson Reuters.
The lower court’s ruling had allowed shareholders to pursue a derivative lawsuit against Allergan's board for allegedly misbranding the company’s Botox treatment despite the fact that a California court had already dismissed the same case. The Delaware Supreme Court decision to overturn it was based on holdings providing that the dismissal of a derivative lawsuit by one court prevents other shareholders from bringing the same case somewhere else.
Read the full article from Thomson Reuters here.
